BIOMAT Database Logo BIOMAT Database Logo

Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. 1999

J T Johannsdottir, and J T Bergthorsson, and S Gretarsdottir, and A K Kristjansson, and G Ragnarsson, and J G Jonasson, and V Egilsson, and S Ingvarsson
Department of Pathology, National University Hospital, Reykjavik, Iceland.

Instability of microsatellite DNA or replication error (RER) is characteristic of tumours caused by mismatch repair (MMR) deficiency. Germline mutations in MMR genes are associated with Hereditary non-polyposis colorectal carcinoma (HNPCC) and somatic mutations in these genes are also found in a substantial fraction of colorectal cancers (CRC). In this study we concurrently screened colorectal tumours for the RER phenotype and loss of heterozygosity (LOH) at MMR gene loci. The RER phenotype was evident in 47/197 (24%) tumours. RER was more commonly detected in young patients (< 50 years) and in tumours located in the proximal colon. RER was positively associated with LOH at the hMSH2/hMSH6 loci on chromosome 2p, where LOH was observed in 46% of the RER+ tumours. LOH at hMLH1 and hPMS1 loci was more frequent in the younger patients (< 50 years). RER was not associated with clinicopathological parameters, such as Duke's stage and tumour differentiation (grade). The RER phenotype was associated with better overall survival, but there was a trend towards significance when multivariate analysis was used. This indicates that loss of MMR genes generate a less aggressive phenotype, and raises the question about RER being a useful indicator of prognosis for CRC patients.

UI MeSH Term Description Entries
D007055 Iceland A country in northern Europe, an island between the Greenland Sea and the North Atlantic Ocean, northwest of the United Kingdom. The capital is Reykjavik.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier

Related Publications

J T Johannsdottir, and J T Bergthorsson, and S Gretarsdottir, and A K Kristjansson, and G Ragnarsson, and J G Jonasson, and V Egilsson, and S Ingvarsson
Mismatch repair genes expression defects & association with clinicopathological characteristics in colorectal carcinoma.
August 2011, The Indian journal of medical research,
J T Johannsdottir, and J T Bergthorsson, and S Gretarsdottir, and A K Kristjansson, and G Ragnarsson, and J G Jonasson, and V Egilsson, and S Ingvarsson
Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis.
July 1998, Hepatology (Baltimore, Md.),
J T Johannsdottir, and J T Bergthorsson, and S Gretarsdottir, and A K Kristjansson, and G Ragnarsson, and J G Jonasson, and V Egilsson, and S Ingvarsson
Frequent loss of heterozygosity at the DNA mismatch-repair loci hMLH1 and hMSH3 in sporadic breast cancer.
March 1999, British journal of cancer,
J T Johannsdottir, and J T Bergthorsson, and S Gretarsdottir, and A K Kristjansson, and G Ragnarsson, and J G Jonasson, and V Egilsson, and S Ingvarsson
Loss of heterozygosity and base substitution at the APRT locus in mismatch-repair-proficient and -deficient colorectal carcinoma cell lines.
November 1996, Molecular and cellular biology,
J T Johannsdottir, and J T Bergthorsson, and S Gretarsdottir, and A K Kristjansson, and G Ragnarsson, and J G Jonasson, and V Egilsson, and S Ingvarsson
Loss of heterozygosity of TP53 is not correlated with clinicopathological variables in sporadic colorectal carcinomas.
January 1999, Anticancer research,
J T Johannsdottir, and J T Bergthorsson, and S Gretarsdottir, and A K Kristjansson, and G Ragnarsson, and J G Jonasson, and V Egilsson, and S Ingvarsson
Differential prognosis of replication error phenotype and loss of heterozygosity in sporadic colorectal cancer.
November 1999, European journal of cancer (Oxford, England : 1990),
J T Johannsdottir, and J T Bergthorsson, and S Gretarsdottir, and A K Kristjansson, and G Ragnarsson, and J G Jonasson, and V Egilsson, and S Ingvarsson
Loss of heterozygosity of tumour suppressor gene loci in human colorectal carcinoma.
January 1994, European journal of cancer (Oxford, England : 1990),
J T Johannsdottir, and J T Bergthorsson, and S Gretarsdottir, and A K Kristjansson, and G Ragnarsson, and J G Jonasson, and V Egilsson, and S Ingvarsson
Loss of heterozygosity and microsatellite instability at the DCC and nm23 loci in Duke's B colorectal carcinoma.
February 1997, Biochemical Society transactions,
J T Johannsdottir, and J T Bergthorsson, and S Gretarsdottir, and A K Kristjansson, and G Ragnarsson, and J G Jonasson, and V Egilsson, and S Ingvarsson
[The relation between DNA replication error and clinicopathological features of colorectal carcinoma].
October 1998, Zhonghua bing li xue za zhi = Chinese journal of pathology,
J T Johannsdottir, and J T Bergthorsson, and S Gretarsdottir, and A K Kristjansson, and G Ragnarsson, and J G Jonasson, and V Egilsson, and S Ingvarsson
Loss of heterozygosity at the ATM locus in colorectal carcinoma.
January 1999, Oncology reports,
Copied contents to your clipboard!